Poly Medicure Limited (POLYMED) - Net Assets
Based on the latest financial reports, Poly Medicure Limited (POLYMED) has net assets worth Rs29.32 Billion INR (≈ $317.14 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs35.87 Billion ≈ $387.94 Million USD) and total liabilities (Rs6.55 Billion ≈ $70.80 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how resilient are Poly Medicure Limited's assets to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rs29.32 Billion |
| % of Total Assets | 81.75% |
| Annual Growth Rate | 27.38% |
| 5-Year Change | 186.43% |
| 10-Year Change | 1109.67% |
| Growth Volatility | 27.23 |
Poly Medicure Limited - Net Assets Trend (2006–2025)
This chart illustrates how Poly Medicure Limited's net assets have evolved over time, based on quarterly financial data. Also explore total assets of Poly Medicure Limited for the complete picture of this company's asset base.
Annual Net Assets for Poly Medicure Limited (2006–2025)
The table below shows the annual net assets of Poly Medicure Limited from 2006 to 2025. For live valuation and market cap data, see Poly Medicure Limited market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | Rs27.66 Billion ≈ $299.10 Million |
+88.13% |
| 2024-03-31 | Rs14.70 Billion ≈ $158.98 Million |
+18.40% |
| 2023-03-31 | Rs12.42 Billion ≈ $134.28 Million |
+14.17% |
| 2022-03-31 | Rs10.87 Billion ≈ $117.61 Million |
+12.63% |
| 2021-03-31 | Rs9.66 Billion ≈ $104.42 Million |
+122.06% |
| 2020-03-31 | Rs4.35 Billion ≈ $47.02 Million |
+14.02% |
| 2019-03-31 | Rs3.81 Billion ≈ $41.24 Million |
+12.73% |
| 2018-03-31 | Rs3.38 Billion ≈ $36.59 Million |
+27.94% |
| 2017-03-31 | Rs2.64 Billion ≈ $28.59 Million |
+15.65% |
| 2016-03-31 | Rs2.29 Billion ≈ $24.73 Million |
+16.54% |
| 2015-03-31 | Rs1.96 Billion ≈ $21.22 Million |
+33.95% |
| 2014-03-31 | Rs1.46 Billion ≈ $15.84 Million |
+30.24% |
| 2013-03-31 | Rs1.12 Billion ≈ $12.16 Million |
+20.19% |
| 2012-03-31 | Rs935.63 Million ≈ $10.12 Million |
+19.68% |
| 2011-03-31 | Rs781.74 Million ≈ $8.45 Million |
+28.92% |
| 2010-03-31 | Rs606.36 Million ≈ $6.56 Million |
+26.40% |
| 2009-03-31 | Rs479.72 Million ≈ $5.19 Million |
+13.95% |
| 2008-03-31 | Rs420.98 Million ≈ $4.55 Million |
+20.28% |
| 2007-03-31 | Rs349.99 Million ≈ $3.79 Million |
+25.64% |
| 2006-03-31 | Rs278.57 Million ≈ $3.01 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Poly Medicure Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1014192800000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Rs10.14 Billion | 36.67% |
| Common Stock | Rs506.63 Million | 1.83% |
| Other Comprehensive Income | Rs3.22 Billion | 11.66% |
| Other Components | Rs13.78 Billion | 49.84% |
| Total Equity | Rs27.66 Billion | 100.00% |
Poly Medicure Limited Competitors by Market Cap
The table below lists competitors of Poly Medicure Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Veritex Holdings Inc
NASDAQ:VBTX
|
$1.66 Billion |
|
Sparebank 1 Nord-Norge
OL:NONG
|
$1.66 Billion |
|
Playa Hotels & Resorts BV
NASDAQ:PLYA
|
$1.66 Billion |
|
Ningbo Ocean Shipping Co. Ltd. A
SHG:601022
|
$1.66 Billion |
|
SLC Agrícola S.A
SA:SLCE3
|
$1.66 Billion |
|
Sobha Limited
NSE:SOBHA
|
$1.66 Billion |
|
S&T Bancorp Inc
NASDAQ:STBA
|
$1.66 Billion |
|
PT Arkora Hydro Tbk
JK:ARKO
|
$1.66 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Poly Medicure Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 14,700,535,000 to 27,656,579,000, a change of 12,956,044,000 (88.1%).
- Net income of 3,385,572,000 contributed positively to equity growth.
- Dividend payments of 303,409,000 reduced retained earnings.
- Share repurchases of 10,003,513,000 reduced equity.
- New share issuances of 10,003,513,000 increased equity.
- Other comprehensive income increased equity by 3,109,243,000.
- Other factors increased equity by 6,764,638,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rs3.39 Billion | +12.24% |
| Dividends Paid | Rs303.41 Million | -1.1% |
| Share Repurchases | Rs10.00 Billion | -36.17% |
| Share Issuances | Rs10.00 Billion | +36.17% |
| Other Comprehensive Income | Rs3.11 Billion | +11.24% |
| Other Changes | Rs6.76 Billion | +24.46% |
| Total Change | Rs- | 88.13% |
Book Value vs Market Value Analysis
This analysis compares Poly Medicure Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.43x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 468.98x to 5.43x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-03-31 | Rs3.22 | Rs1512.10 | x |
| 2007-03-31 | Rs4.04 | Rs1512.10 | x |
| 2008-03-31 | Rs4.54 | Rs1512.10 | x |
| 2009-03-31 | Rs5.42 | Rs1512.10 | x |
| 2010-03-31 | Rs6.86 | Rs1512.10 | x |
| 2011-03-31 | Rs8.86 | Rs1512.10 | x |
| 2012-03-31 | Rs10.60 | Rs1512.10 | x |
| 2013-03-31 | Rs12.76 | Rs1512.10 | x |
| 2014-03-31 | Rs16.60 | Rs1512.10 | x |
| 2015-03-31 | Rs22.25 | Rs1512.10 | x |
| 2016-03-31 | Rs25.91 | Rs1512.10 | x |
| 2017-03-31 | Rs29.96 | Rs1512.10 | x |
| 2018-03-31 | Rs38.34 | Rs1512.10 | x |
| 2019-03-31 | Rs43.22 | Rs1512.10 | x |
| 2020-03-31 | Rs49.25 | Rs1512.10 | x |
| 2021-03-31 | Rs108.30 | Rs1512.10 | x |
| 2022-03-31 | Rs113.32 | Rs1512.10 | x |
| 2023-03-31 | Rs129.31 | Rs1512.10 | x |
| 2024-03-31 | Rs153.10 | Rs1512.10 | x |
| 2025-03-31 | Rs278.67 | Rs1512.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Poly Medicure Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 12.24%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 20.27%
- • Asset Turnover: 0.52x
- • Equity Multiplier: 1.15x
- Recent ROE (12.24%) is below the historical average (20.65%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | 25.76% | 10.18% | 1.23x | 2.06x | Rs43.90 Million |
| 2007 | 23.63% | 9.74% | 1.06x | 2.28x | Rs47.71 Million |
| 2008 | 18.39% | 8.71% | 0.91x | 2.32x | Rs35.12 Million |
| 2009 | 12.49% | 5.31% | 1.05x | 2.23x | Rs11.90 Million |
| 2010 | 26.13% | 11.52% | 1.08x | 2.09x | Rs97.52 Million |
| 2011 | 27.76% | 12.53% | 1.13x | 1.96x | Rs138.65 Million |
| 2012 | 20.82% | 8.97% | 1.19x | 1.94x | Rs101.19 Million |
| 2013 | 21.55% | 9.33% | 1.21x | 1.91x | Rs129.84 Million |
| 2014 | 30.79% | 13.99% | 1.13x | 1.95x | Rs304.48 Million |
| 2015 | 31.77% | 15.97% | 1.07x | 1.86x | Rs427.05 Million |
| 2016 | 21.11% | 11.71% | 1.07x | 1.69x | Rs254.05 Million |
| 2017 | 20.85% | 12.12% | 1.00x | 1.72x | Rs286.84 Million |
| 2018 | 20.87% | 13.56% | 0.92x | 1.67x | Rs367.64 Million |
| 2019 | 17.15% | 10.71% | 0.93x | 1.71x | Rs272.62 Million |
| 2020 | 22.05% | 13.95% | 0.90x | 1.76x | Rs523.96 Million |
| 2021 | 14.07% | 17.28% | 0.64x | 1.27x | Rs393.17 Million |
| 2022 | 13.47% | 15.87% | 0.67x | 1.27x | Rs377.58 Million |
| 2023 | 14.44% | 16.08% | 0.71x | 1.27x | Rs551.20 Million |
| 2024 | 17.57% | 18.77% | 0.74x | 1.26x | Rs1.11 Billion |
| 2025 | 12.24% | 20.27% | 0.52x | 1.15x | Rs619.91 Million |
Industry Comparison
This section compares Poly Medicure Limited's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $1,352,730,000
- Average return on equity (ROE) among peers: 28.80%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Poly Medicure Limited (POLYMED) | Rs29.32 Billion | 25.76% | 0.22x | $1.66 Billion |
| Tarsons Products Limited (TARSONS) | $1.35 Billion | 28.80% | 0.57x | $126.54 Million |
About Poly Medicure Limited
Poly Medicure Limited engages in the manufacture and sale of medical devices in India and internationally. The company offers infusion therapy products, such as I.V Infusion set, extension lines, needle free connector, I.V flow regulator extension set, burette set, three way stop cock, vial access spike, transfer spike, orburator, polyflush, maifolds, polyswab, and arterial blood collection; crit… Read more